Abstract

We attempt to investigate and study the clinical efficacy of letrozole combined with Li Shenbao treatment in patients with ovarian hyporesponsiveness and improve the clinical treatment effect of patients. We selected 153 patients with ovarian hyporesponsiveness in a hospital from January 2018 to December 2020 as the study objects and divided them into 2 groups according to when they enter the in vitro fertilization assisted pregnancy cycle. Control group consists of 76 patients treated with antagonist protocol, while observation group consists of 77 patients treated with letrozole combined with Li Shenbao treatment. The clinical outcomes of the patients with low ovarian hyporesponsiveness were assessed and compared. The results showed that observation group possessed higher M II egg rate, high-quality embryo rate and clinical pregnancy rate than control group (p<0.05). Observation group possessed lower miscarriage rate than control group (p<0.05). The clinical efficacy of Li Shenbao combined with letrozole in patients with ovarian hyporesponsiveness is of good value. This treatment regimen can better improve the ovulation promotion outcome, and to a certain extent, increase the clinical pregnancy rate and reduce the miscarriage rate, and this combination treatment plan has good application prospects.